Class Action Lawsuit Filed Against Erasca, Inc.
A class action lawsuit has been filed against Erasca (NASDAQ: ERAS) over alleged securities fraud and unlawful business practices. The company's stock dropped 10.71% following a patent infringement claim from Revolution Medicines and the disclosure of adverse clinical data for its drug candidate, ERAS-0015.
Topics: clinical trial data patent infringement securities fraud